DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Aktueller Standort:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Corindus CorPath GRX System successfully used in live complex robotic-assisted coronary intervention at EuroPCR 2019

HeartFlow planner changes treatment strategy in nearly half of patients with coronary heart disease

First prospective registry confirms FFR impact treatment plans for patients with CAD

Novel index accurately predicts PCI success post procedure compared to standard measurement metrics

Expert consensus published on use of imaging to guide heart attack treatment

Providing state-of-the-art guidance and clarification concerning IC imaging

Edwards announces milestones for transcatheter mitral program

Algorithm steers catheters to the right spot to treat atrial fibrillation

Noninvasive biomarker for Parkinson's disease possibly found in EEG data

MaxQ AI launches ACCIPIO Ax, slice-level intracranial hemorrhage (ICH) detection and preview in the US and EU

Saudi Arabia Ministry of Health and Masimo to automate national neonatal CCHD screening process using Masimo technology

Press releases may be edited for formatting or style

Eve, available on Radical-7 and Rad-97, combines the power of Masimo SET® pulse oximetry with an automated pre- to post-ductal synchronization algorithm designed to reduce calculation errors during CCHD screening. In addition, Eve simplifies the CCHD screening process by providing visual instructions, animations, and a detailed, easy-to-interpret display of screening results. Saudi Arabia’s automation solution uses Masimo Iris Gateway™ to record and transmit screening results, labeled with unique patient identifiers for both mother and newborn, from Rad-97 and Radical-7 devices to hospital and national electronic medical record (EMR) systems, for efficient, accurate electronic charting and data aggregation in a unified, central health repository.

CCHD affects approximately 2.5 to 3 newborns per 1000 live births4 and requires intervention soon after birth to prevent significant morbidity or mortality; later detection in infants also increases the risk of brain damage.5 In a study of 39,821 infants, CCHD screening sensitivity increased from 63% with physical exam alone to 83% with physical exam and Masimo SET® pulse oximetry.2 In a study of 122,738 infants – the largest CCHD screening study to date – CCHD screening sensitivity increased from 77% to 93% with the combined use of Masimo SET® and clinical assessment.
Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED





About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,6 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response activations and costs.7-9 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,10 and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll.11 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter.

Back to HCB News
<< Pages: 1 - 2

Cardiology Homepage


You Must Be Logged In To Post A Comment

Werben
Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Übersicht
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Gesundheitsdienstleister
Alle Gesundheitsdienstleister-Tools anzeigen
Jobs/Training
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifiziert
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Service-Techniker Forum
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED